NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/09/2026
Back to search
Official data from USPTO
ARGENX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ARGENX
ST13
US500000098957449Class
5, 35, 42, 44
Filing
98957449
Registration
8290605
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
06/09/2026
Trademark type
Word
Nice classes
5, 35, 42, 44
Filing date
01/13/2025
Registration date
06/09/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/09/2026
Last transaction
06/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
First use anywhere
12/17/2021
First use in commerce
12/17/2021
Drawing code
4
Owner type
99
Owner location
Zwijnaarde, BE
Examiner
CHHINA, KARANENDRA S
Law office
M50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Argenx B.V.
Representatives
Edward T. White Williams Mullen
Technical classification
Nice Classes
Class 5Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals and medical preparations for therapeutic purposes in the field of immunology and autoimmune diseases; pharmaceutical preparations for the prevention or treatment of autoimmuneantibody-mediatedneuromuscularhematologicalinflammatoryrespiratorykidneyskintransplantation-related diseases and disorderscancer and diseases of the immune system; compositions of antibodies or fragments of antibodies or derivatives of antibodies with therapeutic properties; antibodies or fragments of antibodies or derivatives of antibodies for the prevention or treatment of autoimmuneantibody-mediatedneuromuscularhematologicalinflammatoryrespiratorykidneyskintransplantation-related diseases and disorderscancer and diseases of the immune system
Class 35
Wholesale and retail store services for therapeutic pharmaceutical preparations in the field of immunology and auto-immune diseases and antibodies or fragments or derivatives of antibodies with therapeutic properties; business administrative services in relation to patient information in the field of immunologydiseases of the immune system and antibody therapeutics; business administration of patient reimbursement programs
Class 42
Research and development in the field of immunologyantibody engineering and autoimmune diseases for therapeutic purposes; therapeutic drug research and development in the field of immunologyantibody technology and autoimmune diseases; scientific and technological servicesresearch relating to immunityautoimmune diseases and antibody engineering for therapeutic purposes; providing medical and scientific research information in the field of therapeutic pharmaceuticalsclinical trialsresearch and development
Class 44
Providing information to patients in the field of auto-immuneantibody-mediatedneuromuscularhematologicalinflammatoryrespiratorykidneyskintransplantation-related diseases and disorderscancer and diseases of the immune system and the treatment thereof; medical consultancy and information services relating to therapeutic biopharmaceutical products; Provision of medical information on therapeutic pharmaceuticalmedicalhealthcare products to customers or patients through an online computer network
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/09/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/21/2026
PUBO
PUBLISHED FOR OPPOSITION
04/21/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/15/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/25/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/19/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/19/2026
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/19/2026
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/13/2026
GNSL
LETTER OF SUSPENSION E-MAILED
02/13/2026
CNSL
SUSPENSION LETTER WRITTEN
02/13/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/19/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/19/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/19/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
09/17/2025
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
09/17/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/19/2025
GNRT
NON-FINAL ACTION E-MAILED
06/19/2025
CNRT
NON-FINAL ACTION WRITTEN
06/19/2025
DOCK
ASSIGNED TO EXAMINER
06/19/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/11/2025
NWAP
NEW APPLICATION ENTERED
01/13/2025
Continuous trademark protection
Get notified about every new filing that threatens ARGENX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.